# Array BioPharma

Source: https://onco.cc/companies/array-biopharma/  
OnCo record `array-biopharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Array BioPharma, of Boulder, Colorado, developed encorafenib and binimetinib, two pills taken together for melanoma with a BRAF mutation. Pfizer bought the company in 2019.

## Summary

Array BioPharma Inc. (formerly Nasdaq: ARRY) was a commercial-stage company in Boulder, Colorado, that discovered and developed targeted small-molecule medicines. At the time of its sale its main products were BRAFTOVI (encorafenib) and MEKTOVI (binimetinib), approved together for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation and being tested in more than 30 trials, including the phase 3 BEACON trial in BRAF-mutant metastatic colorectal cancer. Pfizer agreed on 17 June 2019 to buy Array for USD 48 per share in cash, a total enterprise value of about USD 11.4 billion, through a tender offer, and the merger was completed on 30 July 2019.

## Fields

- Kind: Company
- Last checked: 2026-11-03
- Also known as: Array BioPharma Inc.; NASDAQ:ARRY
- HQ: Boulder, CO
- Type: biotech

## Notes

- No website is recorded: Array no longer operates under its own name and the redirect of its old domain was not checked. Completion on 30 July 2019 is from Array's 8-K of that date. Founding year not read in a primary source and omitted.

## Sources

- Pfizer to acquire Array BioPharma (8-K exhibit 99.1, 17 June 2019): https://www.sec.gov/Archives/edgar/data/1100412/000110465919035823/a19-11481_1ex99d1.htm
- Form 8-K: completion of the merger (30 July 2019): https://www.sec.gov/Archives/edgar/data/1100412/000119312519206255/d733992d8k.htm

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Melanoma](https://onco.cc/cancers/melanoma/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [BRAF](https://onco.cc/targets/braf/), [MEK1/2](https://onco.cc/targets/mek/)
- drugs: [Binimetinib](https://onco.cc/drugs/binimetinib/), [Encorafenib](https://onco.cc/drugs/encorafenib/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/array-biopharma.json